KIAA1524: A novel MLL translocation partner in acute myeloid leukemia
KIAA1524: A novel MLL translocation partner in acute myeloid leukemia
复制标题
DOI：
10.1016/j.leukres.2010.08.017
复制
发表时间：
2011-01-01
影响因子：
2.7
通讯作者：
van den Heuvel-Eibrink, Marry M.
中科院分区：
文献类型：
--
作者：
Coenen, Eva A.;Zwaan, C. Michel;van den Heuvel-Eibrink, Marry M.
染色体11 q23上的混合系白血病基因是急性白血病中反复易位的常见位点。它的混杂特征反映了文献中描述的60多种不同的易位伴侣。通过染色体核型和非典型FISH结果的验证，我们在婴儿急性髓性白血病中鉴定了一个新的易位伴侣，位于3q13.13的KIAA 1524，也被称为“蛋白磷酸酶2A癌抑制剂（CIP 2A）”。该基因最近被鉴定为胃癌中稳定MYC蛋白的原癌基因。KIAA 1524以前从未与血液恶性肿瘤相关，目前的AML病例是描述MLL-KIAA 1524融合的第一例病例。(C)2010爱思唯尔有限公司版权所有。
The Mixed Lineage Leukemia gene on chromosome 11q23 is a frequent site of recurrent translocations in acute leukemias. Its promiscuous character is reflected by the more than 60 different translocation partners described in literature. Prompted by karyotype and atypical FISH results, we identified a new translocation partner in infant acute myeloid leukemia, KIAA1524 on 3q13.13, also known as 'Cancerous Inhibitor of Protein phosphatase 2A (CIP2A)'. This gene was recently identified as a proto-oncogene stabilizing MYC protein in gastric carcinoma. KIAA1524 has never been related to hematologic malignancies before, and the current AML case is the first case in which an MLL-KIAA1524 fusion was described. (C) 2010 Elsevier Ltd. All rights reserved.